Lucid Diagnostics Inc Total Liabilities
Lucid Diagnostics Inc total liabilities. Based on the latest financial reports, Lucid Diagnostics Inc (LUCD) has total liabilities worth $28.02 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Lucid Diagnostics Inc (LUCD) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lucid Diagnostics Inc (2018–2025)
Total liabilities of Lucid Diagnostics Inc from 2018 to 2025. This chart illustrates how Lucid Diagnostics Inc's total liabilities have evolved over time, based on quarterly financial data.
Lucid Diagnostics Inc Competitors by Total Liabilities
The table below lists competitors of Lucid Diagnostics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dallasnews Corp
NASDAQ:DALN
|
USA | $37.75 Million |
|
Samsung Pharm
KO:001360
|
Korea | ₩44.04 Billion |
|
FIH Mobile Limited
F:FW3
|
Germany | €2.36 Billion |
|
Blue Cap AG
XETRA:B7E
|
Germany | €112.79 Million |
|
LOT VACUUM Co. Ltd
KQ:083310
|
Korea | ₩88.72 Billion |
|
Y-Entec Co. Ltd
KQ:067900
|
Korea | ₩166.64 Billion |
|
Articore Group Ltd
AU:ATG
|
Australia | AU$66.91 Million |
|
Qua Granite Hayal Yapi ve Urunleri Sanayi Ticaret AS
IS:QUAGR
|
Turkey | TL10.51 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Lucid Diagnostics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LUCD total assets.
Liquidity & Leverage Metrics
Lucid Diagnostics Inc Total Liabilities Ratios Explained
Lucid Diagnostics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lucid Diagnostics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lucid Diagnostics Inc (2018–2025)
The table below shows the annual total liabilities of Lucid Diagnostics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $29.51 Million | +16.53% |
| 2024-12-31 | $25.32 Million | -14.39% |
| 2023-12-31 | $29.58 Million | +212.63% |
| 2022-12-31 | $9.46 Million | +122.11% |
| 2021-12-31 | $4.26 Million | -72.89% |
| 2020-12-31 | $15.71 Million | +147.71% |
| 2019-12-31 | $6.34 Million | +487.07% |
| 2018-12-31 | $1.08 Million | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with th… Read more